|
Acronym |
Meaning |
|
ABG |
Arterial Blood Gas |
|
AIHA |
Autoimmune Hemolytic Anemia |
|
AE |
Adverse Event |
|
Alb |
Albumin |
|
ALC |
Absolute Lymphocyte Count |
|
ALL |
Acute Lymphoblastic Leukemia |
|
AML |
Acute Myeloid Leukemia |
|
ANC |
Absolute Neutrophil Count |
|
ASCO |
American Society of Clinical Oncology |
|
ASH |
American Society of Hematology |
|
B2M |
Beta2-Microglobulin |
|
BCL-2 |
B-cell lymphoma 2 |
|
BCR |
B-cell Receptor |
|
BM |
Bone Marrow |
|
BMBx |
Bone Marrow Biopsy |
|
BMT |
Bone Marrow Transplant |
|
BR |
Bendamustine and Rituximab |
|
BTK |
Bruton’s Tyrosine Kinase |
|
BUN |
Blood Urea Nitrogen |
|
Ca |
Calcium |
|
CAM |
Complementary and Alternative Medicine |
|
CAR-T |
Chimeric Antigen Receptor T-cell |
|
CBC |
Complete Blood Count |
|
CD |
Cluster of Differentiation |
|
CIT |
Chemo immuno Therapy |
|
CK |
Complex Karotype |
|
Cl |
Chlorine |
|
CLL |
Chronic Lymphocytic Leukemia |
|
CML |
Chronic Myeloid Leukemia |
|
CO2 |
Carbon Dioxide |
|
CP |
Convalescent Plasma |
|
Cr |
Creatinine |
|
CR |
Complete Response |
|
CRS |
Cytokine Release Syndrome |
|
Del (17p) |
17p Deletion |
|
DFS |
Disease Free Survival |
|
DLBCL |
Diffuse Large B-Cell Lymphoma |
|
DoR |
Duration of Response |
|
Dx |
Diagnosis |
|
Dz |
Disease |
|
EHA |
European Hematology Association |
|
EOT |
End of Treatment |
|
FCR |
Fludarabine, Cyclophosphamide, Rituximab |
|
FISH |
Fluorescence In Situ Hybridization |
|
GVHD |
Graft Versus Host Disease |
|
HCT |
Hematocrit |
|
HDMP |
High dose methyl-prednisolone |
|
HGB |
Hemoglobin level |
|
HLA |
Human Leukocyte Antigen |
|
HSCT |
Hematopoietic Stem Cell Transplant |
|
Hx |
History |
|
IAHA |
Idiopathic Autoimmune Hemolytic Anemia |
|
Ibr |
Ibrutinib |
|
IRC |
Independent Review Committee |
|
ITP |
Idiopathic (or Immune) Thrombocytopenic Purpura |
|
IwCLL |
International Workshop on CLL |
|
K |
Potassium |
|
LD |
Longest Diameter |
|
LDH |
Lactate Dehydrogenase |
|
LDT |
Lymphocyte Doubling Time |
|
LN |
Lymph Node |
|
MAB |
Monoclonal Antibodies |
|
MBL |
Monoclonal B-Cell Lymphocytosis |
|
MCH |
Mean Corpuscular Hemoglobin |
|
MCHC |
Mean Corpuscular Hemoglobin Concentration |
|
MCV |
Mean Corpuscular Volume |
|
MDS |
Myelodysplastic Syndromes |
|
MPV |
Mean Platelet Volume |
|
MRD |
Minimal or Measurable Residual Disease |
|
Na |
Sodium |
|
NGS |
Next Generation Sequencing |
|
O2 |
Oxygen |
|
ORR |
Overall Response Rate |
|
OS |
Overall Survival |
|
PB |
Peripheral Blood |
|
PCR |
Polymerase Chain Reaction |
|
PD |
Progressive Disease |
|
PFS |
Progression Free Survival |
|
PI3K |
Phosphoinositide 3-kinase |
|
PLT |
Platelets |
|
PR |
Partial Response/Partial Remission |
|
Pt |
Patient |
|
R |
Rituximab |
|
R/R |
Relapsed/Refractory |
|
RBC |
Red Blood Cell |
|
RCHOP |
Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone |
|
RDW |
Red cell Distribution Width |
|
RT |
Richter’s Transformation |
|
SCT |
Stem Cell Transplant |
|
SGPT |
Serum Glutamic Pyruvic Transaminase |
|
SL |
Synthetic Lethality |
|
SLL |
Small Lymphocytic Lymphoma |
|
TB4T |
Test Before Treat |
|
TBI |
Total Body Irradiation |
|
TKI |
Tyrosine Kinase Inhibitors |
|
TLS |
Tumor Lysis Syndrome |
|
TN |
Treatment Naive |
|
TTNT |
Time to Next Treatment |
|
TTP |
Time to Progression |
|
TTT |
Time to Treat |
|
Tx |
Treatment |
|
URI |
Upper Respiratory Infection |
|
VenR |
Venetoclax-Rituximab |
|
Vx |
Venetoclax |
|
W&W |
Watch and Wait |
|
WBC |
White Blood Cells |
|
WM |
Waldenstrom’s Macroglobulinemia |
Updated: February 4, 2021
-
Pingback: ESH 2014: Prof. Michael Hallek Discusses Clinical Trial Goals in CLL - CLL Society
-
Pingback: Clinical Trial Goals in CLL
-
Pingback: ASH 2014: Dr. Jan Burger on Ibrutinib Resistance in CLL (chronic lymphocytic leukemia): Next Steps: Transplants and Trials (Part 1) - CLL Society
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL
-
Pingback: New Targeted Therapies for Chronic Lymphocytic Leukemia
-
Pingback: Complex Karyotype in CLL Predicts Inferior Outcomes with Ibrutinib Therapy - CLL Society
-
Pingback: Symptoms of Chronic Lymphocytic Leukemia - CLL Society
-
Pingback: Diagnosis of Chronic Lymphocytic Leukemia - CLL Society
-
Pingback: ASH 2015: Dr. Stephan Stilgenbauer on Dramatic Responses to Venetoclax in relapsed/ refractory (R/R) 17p deleted CLL - CLL Society